NASDAQ · RPIDHealthcareLab Analytical Instruments

Rapid Micro Biosystems, Inc. Class A Common Stock (RPID)

$0.6814−1.53%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$0.68▼ 74.76% in range
Nov 4, 2025Low $0.68 · High $4.68Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Rapid Micro Biosystems closed at $0.68 on Nov 4, down 1.53%, within 0.0% of its 52-week closing low. Volume of 209.2K shares was 1.40× its 20-day average (above normal).

Split-adjusted performance: -27.7% over one month, -73.1% over six months, -75.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $8.05M, up 10.9% from a year earlier, with a net margin of -160.5%.

Short interest was 888.6K shares at the Oct 15 settlement, up 4.1% from the prior report (3.9% of float, 3.8 days to cover).

Market cap$34.2M50.2M shares
Revenue · quarter$8.1M+10.9% YoY
Diluted EPS$-0.27—
P/E · TTM—P/S 1.0×
Net margin-160.5%Gross 15.0%
Dividend yieldNone
52-week range0.68 – 4.68−85.4% from high
Volume209.2K1.40× 20-day avg
Volatility · 60d57.2%Annualised
Short % of float3.9%3.8 days to cover
Net cash$627.0KCash $19.8M
Next earnings—Not scheduled
Split-adjusted performance
1W −14.8%1M −27.7%3M −67.2%6M −73.1%YTD −76.5%1Y −75.2%3Y −29.8%5Y −96.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Lab Analytical Instruments

Percentile among 22 companies (100 = best)

6-month momentum5
Revenue growth68
Net margin19
Value (low P/E)—
Size14

Industry medians: 6-month return +33.8%, revenue growth +4.9%, net margin −19.0%, P/E 38.3×.

Short interest

Details →
Shares short888.6K+4.1% vs prior
Days to cover3.8Settled Oct 15
% of float3.9%
Short vol. 10d49.3%of daily volume

Closest peers by size in Lab Analytical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
RPIDRapid Micro Biosystems$0.6814−1.53%−73.1%+10.9%−160.5%—$34.2M
EYPTEyePoint$0.3950−1.23%−97.0%−90.5%−18633.1%—$34.1MCompare
PRPOPrecipio$19.57+5.10%−34.7%+24.7%−3.1%—$35.0MCompare
HBIOHarvard Bioscience$8.61−0.69%+18.9%+11.1%−12.8%—$39.2MCompare
BNGOBionano Genomics$1.19−0.83%−6.3%+21.4%−90.8%—$16.6MCompare
SEERSeer$1.70−1.73%−10.1%−23.4%−544.8%—$94.1MCompare
ASTCAstrotech Corporation (DE)$4.51−7.20%+62.2%−42.7%−2592.1%—$9.5MCompare
QTRXQuanterix$3.04+3.40%−7.6%+34.4%−148.7%—$143.8MCompare
NAUTNautilus Biotechnolgy$2.29−2.55%−22.1%—−6682.1%—$291.7MCompare

Quick answers

What does Rapid Micro Biosystems do?
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye.
What is RPID's market cap?
$34.18M, based on the Nov 4 close of $0.68.
Does Rapid Micro Biosystems pay a dividend?
No regular cash dividend has been paid in the last year.
How much of RPID is sold short?
888.6K shares, 3.9% of float, as of Oct 15, 2026.
What sector is RPID in?
Healthcare, in the Lab Analytical Instruments industry.

About Rapid Micro Biosystems

Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.

HQ: Lexington, MA171 employeesListed Jul 15, 2021rapidmicrobio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology